Search
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744] … [A245854] B-cell maturation antigen (BCMA) is a transmembrane glycoprotein member of the tumor necrosis factor receptor superfamily 17 (TNFRSF17) which is used as a biomarker for multiple myeloma.
EB05
go.drugbank.com/drugs/DB16477InvestigationalEB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS.
Pancrelipase amylase
go.drugbank.com/drugs/DB11065ApprovedInvestigational[L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]
Beremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigationalDeveloped by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).
Eltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalEltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Etazolate
go.drugbank.com/drugs/DB05881InvestigationalEHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.
Nelfinavir
go.drugbank.com/drugs/DB00220ApprovedInvestigationalNelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the...
Cyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Aficamten
go.drugbank.com/drugs/DB18490ApprovedInvestigationalAficamten is a cardiac myosin inhibitor. Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symp...
CERE-120
go.drugbank.com/drugs/DB05637InvestigationalIt was under investigation in clinical trials for the treatment of Parkinson's Disease. … CERE-120 is an investigational drug consisting of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor.